Answers are grounded in this paper and cite their sources.
A provocative psychopharmacology paper from an earlier era, 1 purporting to show bias in clinical trials for schizophrenia, actually elicits a more sobering interpretation—namely, that the treatment of patients with schizophrenia is no better than a ‘trial-and-error’ approach for each patient with each drug. For sure, it’s “individualized” or “personalized” treatment—to the extent that treatment (and lesser so adverse effects) is highly variable across each patient - though this is certainly a long way off from the genetically-guided immunotherapy and individually tailored cancer therapy that characterizes personalized medicine (PM) as having come of age in healthcare and science. 2 , 3 , 4 , 5 Moreover, biomarker tests are emerging across several areas of medicine that inform and guide molecular targeted therapies that have transformative potential for how we deliver care.
No takes yet. Share an insight, caveat, or question.
Buckley et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: